Diclofenac (Topical Voltaren) for Pain & Inflammation — Regenerative Therapies
Non-selective NSAID available as FDA-approved OTC topical gel for osteoarthritis pain with strong evidence for efficacy and improved GI safety profile.
Overview
Diclofenac is a phenylacetic acid derivative and potent non-selective cyclooxygenase (COX-1/COX-2) inhibitor that has been one of the most widely prescribed NSAIDs globally since its introduction in 1973. The topical gel formulation (Voltaren Arthritis Pain, 1% diclofenac sodium) received FDA approval for OTC sale in 2020 for the treatment of arthritis pain in hands, wrists, elbows, feet, ankles, and knees, making it the first prescription-strength NSAID available without a prescription in the United States. Topical diclofenac delivers drug directly to affected joints and surrounding tissues while achieving systemic absorption that is only 5-10% of equivalent oral doses, dramatically reducing the risk of GI, cardiovascular, and renal adverse effects associated with systemic NSAIDs. Multiple randomized controlled trials and Cochrane reviews confirm that topical diclofenac provides clinically meaningful pain relief comparable to oral NSAIDs for knee and hand osteoarthritis. A meta-analysis of 7,688 patients found that topical diclofenac achieved a 50% pain reduction in 60% of patients, with NNT (number needed to treat) of 6.4. The gel formulation achieves therapeutic concentrations in synovial fluid within 2 hours of application while maintaining plasma levels below those associated with systemic side effects.
Indications
- FDA-approved (OTC): Arthritis pain in accessible joints (hands, wrists, elbows, knees, ankles, feet)
- FDA-approved (Rx): Osteoarthritis pain (Voltaren Gel 1%)
- FDA-approved (Rx): Actinic keratoses (Solaraze Gel 3%)
- Strong evidence: Knee and hand osteoarthritis (Cochrane-confirmed)
- Moderate evidence: Acute sports injuries (sprains, strains, contusions)
- Moderate evidence: Localized tendinopathy and bursitis
Mechanism of Action
Diclofenac inhibits both COX-1 and COX-2 enzymes in local tissues, blocking the conversion of arachidonic acid to prostaglandins (PGE2, PGI2) and thromboxane A2
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Diclofenac sodium gel 1% | 4 g per joint (lower extremity) | Four times daily | OTC Voltaren Arthritis Pain; max 16 g/day per lower extremity joint |
| Diclofenac sodium gel 1% | 2 g per joint (upper extremity) | Four times daily | Hands, wrists, elbows; max 8 g/day per upper extremity joint |
| Diclofenac solution 1.5% | 40 drops per knee | Four times daily | Pennsaid solution for knee OA only |
| Diclofenac epolamine patch | 1.3% patch | Twice daily | Flector Patch for acute strains/sprains |
Evidence Grade
GRADE C
Safety & Contraindications
- Application site reactions (dryness, rash, itching) in 5-10% of patients
- Systemic absorption is only 5-10% of oral — dramatically lower GI, CV, and renal risk
- Still carries NSAID black box warning: CV and GI risk — but clinically minimal for topical
- Avoid applying to broken skin, wounds, or mucous membranes
- Do not use with occlusive dressings (increases absorption and side effects)
- Avoid sun exposure to treated areas (photosensitivity risk with 3% formulation)